Structure Therapeutics Inc (GPCR)
37.69
+1.32
(+3.63%)
USD |
NASDAQ |
Nov 14, 16:00
37.80
+0.11
(+0.29%)
After-Hours: 20:00
Structure Therapeutics Net Income (TTM): -100.44M for June 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | -100.44M |
| March 31, 2024 | -97.68M |
| December 31, 2023 | -89.62M |
| September 30, 2023 | -76.99M |
| Date | Value |
|---|---|
| June 30, 2023 | -65.55M |
| March 31, 2023 | -56.22M |
| December 31, 2022 | -51.32M |
| September 30, 2022 | -51.12M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-100.44M
Minimum
Jun 2024
-51.12M
Maximum
Sep 2022
-73.62M
Average
-71.27M
Median
Net Income (TTM) Benchmarks
| Viking Therapeutics Inc | -99.15M |
| Eli Lilly and Co | 8.370B |
| Novo Nordisk AS | 13.79B |
| Pfizer Inc | 4.252B |
| Amgen Inc | 4.23B |